Bausch Health Companies Inc.
Registration:
1
of
1
(2021-03-31
to
2021-10-16)
Details Regarding the Identified Subject Matter
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
To achieve provincial drug listing for Bausch's SILIQ ® (brodalumab) for the Treatment of Plaque Psoriasis
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|